HCV Drug Discovery: A Multidisciplinary Effort to Find a Cure
Walter and Eliza Hall Institute of Medical Research
1g Royal Parade
See more events from
In the late 80’s / early 90’s a new viral disease was recognised that was causing liver damage (hepatitis) in millions of individuals worldwide. Thanks to the excellent scientific discoveries of researchers at Chiron Corporation, this non-A, non-B viral hepatitis was characterised as a +-stranded RNA virus and aptly given the name Hepatitis C. Infecting approximately 4 times the number of people as HIV, this disease needed a robust curative regimen. It took 18 years from our initial efforts at Merck to the approval of first direct acting drug Vanihep. The discovery of this drug and the next generation HCV NS3 protease inhibitor found in Zepatier will be discussed in a manner that gives insights into the complexities of the drug discovery process and the many different types of science and scientists required for success.
No registration is required.